Valuation: Petros Pharmaceuticals, Inc.

Market Cap 169K 149K 140K 128K 240K 16.24M 241K 1.68M 651K 8.3M 636K 623K 26.67M P/E 2024
-0.12x
P/E 2025 -0.01x
Enterprise Value -4.97M -4.36M -4.12M -3.75M -7.02M -476M -7.07M -49.26M -19.08M -243M -18.65M -18.25M -782M EV / Sales 2024
1.49x
EV / Sales 2025 -
Free-Float
74.41%
Yield 2024 *
-
Yield 2025 -
1 day-13.79%
1 week+25.00%
Current month+38.89%
3 months-16.67%
6 months-28.57%
Current year-37.11%
1 week 0
Extreme 0.004
0.01
1 month 0
Extreme 0.0035
0.01
Current year 0
Extreme 0.0025
0.01
1 year 0
Extreme 0.0017
0.03
3 years 0
Extreme 0.0017
56.75
5 years 0
Extreme 0.0017
1,300
10 years 0
Extreme 0.0017
1,489.98
Manager TitleAgeSince
Director of Finance/CFO 66 -
President 49 30/11/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 62 30/11/2020
Director/Board Member 67 30/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
05/06/26 Free

Director

1,875,000 4.4251%
02/01/26 Free

Director

500,000 1.1800%
02/01/26 Free

Chairperson

500,000 1.1800%
Change 5-day change 1-year change 3-year change Capi.($)
-13.79%+25.00%-80.47%-99.99% 169K
+2.12%+7.87%+0.27%+37.62% 45.44B
-1.63%-5.05%-47.92%+126.16% 11.81B
+2.59%-1.45%-6.92%+112.99% 5.54B
+1.05%-3.11%+44.96% - 4.28B
-5.25%-11.61% - - 1.94B
+1.91%+4.44%+10.36%-30.60% 1.54B
+0.08%-1.95%-36.69% - 1.01B
-0.61%-3.19%+12.27%+155.26% 960M
-1.14%-5.77%+28.32%+43.76% 859M
Average -1.47%-1.98%-8.42%+49.32% 7.34B
Weighted average by Cap. +1.19%+3.42%-5.39%+59.95%

Financials

2024 2025
Net sales 5.11M 4.49M 4.24M 3.86M 7.23M 490M 7.28M 50.7M 19.64M 250M 19.19M 18.78M 804M -
Net income -14.32M -12.56M -11.87M -10.81M -20.24M -1.37B -20.39M -142M -55M -701M -53.76M -52.6M -2.25B 1.91M 1.68M 1.59M 1.45M 2.71M 183M 2.72M 18.98M 7.35M 93.7M 7.18M 7.03M 301M
Net Debt 3.68M 3.23M 3.05M 2.78M 5.2M 352M 5.23M 36.46M 14.12M 180M 13.8M 13.5M 579M -5.14M -4.51M -4.26M -3.88M -7.26M -492M -7.31M -50.94M -19.73M -252M -19.29M -18.87M -808M
Logo Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.
Employees
3
Date Price Change Volume
25/09/26 US$0.004000 -20.00% 13,006
24/09/26 US$0.005000 +25.00% 78,177
22/09/26 US$0.004000 -.--% 432
21/09/26 US$0.004000 -.--% 51,175
18/09/26 US$0.004000 -34.21% 28,915

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTPI Stock